Secondary analysis of the phase III ABC-06 trial in advanced biliary cancer: raised CA19-9, CEA and CA125 each independently predicted shorter overall survival (n=120); time to QoL deterioration did not differ between ASC + FOLFOX and ASC alone (n=76; aHR 0.97).
Secondary analysisn = 162
Lamarca et al. Prognostic markers, quality of life (QoL) and value of health (V-He) in advanced biliary cancers (ABC) treated with second-line active symptom control (ASC) alone or ASC with oxaliplatin-5-FU chemotherapy (ASC + FOLFOX) in the randomised phase III, multicentre, open-label ABC-06 clinical trial